REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in December

REGENXBIO Inc. (NASDAQ:RGNX) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 6,230,000 shares, a growth of 18.4% from the November 30th total of 5,260,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is presently 6.1 days.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price target on shares of REGENXBIO in a report on Wednesday, December 11th. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Morgan Stanley reissued an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Raymond James reaffirmed an “outperform” rating and set a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Stock Down 5.8 %

Shares of RGNX opened at $7.41 on Monday. The firm has a market cap of $367.13 million, a price-to-earnings ratio of -1.47 and a beta of 1.24. The company’s fifty day moving average is $9.27 and its 200-day moving average is $10.94. REGENXBIO has a 12 month low of $7.15 and a 12 month high of $28.80.

Insiders Place Their Bets

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now directly owns 11,286 shares in the company, valued at approximately $114,101.46. This represents a 46.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 13.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Louisiana State Employees Retirement System boosted its stake in REGENXBIO by 14.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 22,800 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 2,800 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of REGENXBIO by 9.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company’s stock valued at $3,972,000 after acquiring an additional 28,846 shares in the last quarter. Principal Financial Group Inc. grew its stake in REGENXBIO by 4.3% in the second quarter. Principal Financial Group Inc. now owns 225,417 shares of the biotechnology company’s stock valued at $2,637,000 after purchasing an additional 9,206 shares in the last quarter. Maryland State Retirement & Pension System increased its position in shares of REGENXBIO by 7.2% during the 2nd quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,067 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of REGENXBIO by 8.2% in the 2nd quarter. Rhumbline Advisers now owns 118,526 shares of the biotechnology company’s stock valued at $1,387,000 after buying an additional 8,987 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.